Translational Dev Acquisition Corp Financials
This page shows Translational Dev Acquisition Corp (TDACU) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Translational Dev Acquisition Corp passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
For every $1 of reported earnings, Translational Dev Acquisition Corp generates $11.99 in operating cash flow (-$851K OCF vs -$71K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Translational Dev Acquisition Corp reported -$71K in net income in fiscal year 2024. This represents an increase of 85.4% from the prior year.
Translational Dev Acquisition Corp held $438K in cash against $0 in long-term debt as of fiscal year 2024.
Translational Dev Acquisition Corp had 0 shares outstanding in fiscal year 2024.
TDACU Income Statement
| Metric | Q3'25 | Q3'25 | Q3'25 | Q3'24 | Q3'24 | Q3'24 | Q3'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $214K-3.4% | $221K-36.3% | $347K | N/A | $61K+3537.0% | $2K | $0 | N/A |
| Operating Income | -$214K+3.4% | -$221K+36.3% | -$347K | N/A | -$61K-3537.0% | -$2K | $0 | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | $0 | N/A | N/A | N/A | N/A | N/A |
| Net Income | $1.7M+2.3% | $1.6M+9.5% | $1.5M | N/A | -$61K-3537.0% | -$2K | $0 | N/A |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
TDACU Balance Sheet
| Metric | Q3'25 | Q3'25 | Q3'25 | Q3'24 | Q3'24 | Q3'24 | Q3'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $180.0M+1.0% | $178.2M+0.9% | $176.6M+0.9% | $175.0M | N/A | N/A | N/A | $2K |
| Current Assets | $81K-48.4% | $156K-62.4% | $415K-36.1% | $650K | N/A | N/A | N/A | $2K |
| Cash & Equivalents | $47K+33.7% | $35K-82.9% | $207K-52.8% | $438K+95.6% | $224K+211.1% | $72K | N/A | $2K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $186.4M+1.1% | $184.3M+1.0% | $182.5M+1.1% | $180.6M | N/A | N/A | N/A | $510K |
| Current Liabilities | $423K+48.5% | $285K-11.8% | $323K+53.5% | $210K | N/A | N/A | N/A | $510K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$6.4M-3.5% | -$6.2M-3.7% | -$5.9M-6.2% | -$5.6M-881.0% | -$571K-12.0% | -$509K-0.3% | -$508K0.0% | -$508K |
| Retained Earnings | -$6.4M-3.5% | -$6.2M-3.7% | -$5.9M-6.2% | -$5.6M | N/A | N/A | N/A | -$533K |
TDACU Cash Flow Statement
| Metric | Q3'25 | Q3'25 | Q3'25 | Q3'24 | Q3'24 | Q3'24 | Q3'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$88K+48.6% | -$171K+26.0% | -$232K+71.4% | -$811K | N/A | N/A | N/A | N/A |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | N/A | N/A | N/A | $175.3M+90939.0% | $193K | N/A | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
TDACU Financial Ratios
| Metric | Q3'25 | Q3'25 | Q3'25 | Q3'24 | Q3'24 | Q3'24 | Q3'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | 0.9%0.0pp | 0.9%+0.1pp | 0.8% | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | 0.19-0.4 | 0.55-0.7 | 1.29-1.8 | 3.09 | N/A | N/A | N/A | 0.00 |
| Debt-to-Equity | -29.21+0.7 | -29.90+0.8 | -30.71+1.6 | -32.26 | N/A | N/A | N/A | -1.00 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$5.6M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Frequently Asked Questions
Is Translational Dev Acquisition Corp profitable?
No, Translational Dev Acquisition Corp (TDACU) reported a net income of -$71K in fiscal year 2024.
What is Translational Dev Acquisition Corp's operating cash flow?
Translational Dev Acquisition Corp (TDACU) generated -$851K in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Translational Dev Acquisition Corp's total assets?
Translational Dev Acquisition Corp (TDACU) had $175.0M in total assets as of fiscal year 2024, including both current and long-term assets.
How many shares does Translational Dev Acquisition Corp have outstanding?
Translational Dev Acquisition Corp (TDACU) had 0 shares outstanding as of fiscal year 2024.
What is Translational Dev Acquisition Corp's current ratio?
Translational Dev Acquisition Corp (TDACU) had a current ratio of 3.09 as of fiscal year 2024, which is generally considered healthy.
What is Translational Dev Acquisition Corp's debt-to-equity ratio?
Translational Dev Acquisition Corp (TDACU) had a debt-to-equity ratio of -32.26 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Translational Dev Acquisition Corp's return on assets (ROA)?
Translational Dev Acquisition Corp (TDACU) had a return on assets of -0.0% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Translational Dev Acquisition Corp's cash runway?
Based on fiscal year 2024 data, Translational Dev Acquisition Corp (TDACU) had $438K in cash against an annual operating cash burn of $851K. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Translational Dev Acquisition Corp's debt-to-equity ratio negative or unusual?
Translational Dev Acquisition Corp (TDACU) has negative shareholder equity of -$5.6M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Translational Dev Acquisition Corp's Piotroski F-Score?
Translational Dev Acquisition Corp (TDACU) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Translational Dev Acquisition Corp's earnings high quality?
Translational Dev Acquisition Corp (TDACU) has an earnings quality ratio of 11.99x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.